Opinion|Videos|November 27, 2024
AHA Guidelines and Patient Mortality
Key Takeaways
- ASCVD involves plaque buildup in arteries, causing narrowing and hardening, which can lead to cardiovascular events.
- Key risk factors include high cholesterol, hypertension, smoking, diabetes, and sedentary lifestyle.
Panelists discuss how effective management of dyslipidemia through adherence to AHA guidelines is crucial for reducing cardiovascular mortality rates and improving patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss atherosclerotic cardiovascular disease (ASCVD).
Advertisement
Related to this article
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
Anaphylm Is Back at the FDA: A Clinician FAQ on Needle-Free Epinephrine
5